The Anti-tumor Activities Of Tumor Antigen Peptide M1-10

Transcription factor FOXM1(Forkhead box M1)is a member of the FOX transcription factor family.FOXM1 is not only involved in the formation and progression of cancer,but also is closely related to the prognosis of tumor patients.In view of this,FOXM1 has become an important target for anticancer drug development.In addition,FOXM1 can also be used as the source protein of tumor antigens.It has been confirmed that the peptides derived from FOXM1 can trigger the body to produce HLA-A2-restricted cytotoxic T cell responses and specifically kill tumors.In recent years,tumor vaccines have become an important means of cancer treatment in cancer immunotherapy.Tumor antigen is an antigenic substance produced by tumor cells,which is generally an oligopeptide composed of 8 to 11 amino acids.According to their categories,tumor antigens are divided into tumor-specific antigens(TSA),tumor-associated antigens(TAA),the former is only expressed in tumors,while the latter are expressed in both tumors and normal tissues.According to the amino acid composition of tumor antigens,the corresponding antigenic peptides can be designed and used as tumor vaccines to trigger the body’s immune response.In Based on bioinformatics analysis,a transcription factor FOXM1-derived tumor antigen peptide M1-10 was screened out.Through the experiments of lymphocyte proliferation,interferon gamma release,and cell killing,we found that M1-10 peptide could stimulate the immune memory in vivo and produce better effects when combined with HJURP,MELK,VEGFR1,and VEGFR2-derived four antigens.Tumor pre-immunization experiments were carried out with the mouse models of grafted breast cancer and MMTV-Py MT primary breast cancer.Compared with the control group,M1-10 alone produced significant anti-tumor effects and M1-10 plus four antigen generated stronger anti-tumor effects.In addition,immunohistochemical experiments found that infiltrating CD8 T cells increased in the tumor tissue of mice after pre-immunization.In conclusion,the study developed the tumor antigen peptide M1-10 with a strong immunogenicity,which could result in effective tumor immunity when used alone or combined with other tumor antigen peptides.This conclusion provides further insights into the antitumor mechanism of FOXM1.